Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds and APIs
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Breadcrumb
Home
Evaluate Vantage Homepage
Pharmaceutical Companies
NPS Pharmaceuticals
February 16, 2016
Zealand plays catch-up with Shire in short bowel syndrome
April 10, 2015
Shire shines as a post-AbbVie solo act
January 15, 2015
Mega-merger drought fails to impede record-breaking acquisition year
January 12, 2015
Natpara risk overshadows Shire’s NPS takeout
November 04, 2014
PD-1s make way for the next wave of blockbuster launches
October 16, 2014
Shabbvie is dead; long live Shire
October 10, 2014
Upcoming events: Rett data for Neuren while NPS awaits Natpara approval
September 22, 2014
Still unpartnered, but now worth a lot more
August 29, 2014
Upcoming events: FDA panels take on liraglutide and Natpara
July 22, 2014
Small-molecule launches hold their own
February 19, 2014
Vantage Point – Four-tier drug plans thrust affordability into spotlight
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
April 20, 2022
Genetic Medicine: The Next Generation
March 18, 2022
PD(L)anner - March 2022
Editor's Picks
May 05, 2022
Bristol needs to get fresh
May 04, 2022
The next generation of diabetes technology
April 25, 2022
Nkarta: at least as good as Fate, at a tenth of the price
April 26, 2022
How Gal appointment could influence strategy at Novartis
May 01, 2020
US FDA approval tracker: April
